Engineers Gate Manager LP purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 93,040 shares of the medical equipment provider’s stock, valued at approximately $3,414,000.
Several other hedge funds have also modified their holdings of HOLX. Hall Laurie J Trustee grew its stake in Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after purchasing an additional 225 shares in the last quarter. Commonwealth Bank of Australia grew its stake in Hologic by 31.0% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after purchasing an additional 600 shares in the last quarter. Grove Bank & Trust grew its stake in Hologic by 115.8% in the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 1,535 shares in the last quarter. National Asset Management Inc. purchased a new position in Hologic in the second quarter valued at about $203,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in Hologic in the second quarter valued at about $213,000. Institutional investors and hedge funds own 98.09% of the company’s stock.
In related news, Director Elaine Ullian sold 9,282 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,972 shares of company stock valued at $1,385,977. 0.79% of the stock is currently owned by corporate insiders.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.01. The company had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.52 EPS. research analysts expect that Hologic, Inc. will post 2.12 earnings per share for the current year.
A number of research analysts have commented on HOLX shares. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Needham & Company LLC restated a “buy” rating and issued a $50.00 target price on shares of Hologic in a research note on Monday, October 2nd. Stifel Nicolaus restated a “buy” rating and issued a $45.00 target price (down previously from $48.00) on shares of Hologic in a research note on Monday, October 9th. Jefferies Group restated a “buy” rating and issued a $44.00 target price (down previously from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $45.00 target price (down previously from $50.00) on shares of Hologic in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the stock. Hologic presently has a consensus rating of “Buy” and an average target price of $47.38.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.